Events Archives - Page 100 of 128

5 minute read

Reported Late Thursday, ANAVEX2–73 Phase 2B/3 Study Met Primary And Key Secondary Endpoints, Showing Statistically Significant Reduction Of Clinical Decline In Global Clinical Study Of Patients With Early Alzheimer’s Disease; Shares Currently Halted

December 2, 2:10 AM

Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically

AVXL

3 minute read

Reported Late Thursday, UroGen Announces New Data From The OLYMPUS Trial that Shows Median Durability Of Response Of 28.9 Months For JELMYTO, A Non-Surgical, Chemoablative Treatment For Adults With Low-Grade Upper Tract Urothelial Cancer

By Benzinga Newsdesk

December 2, 2:01 AM

--Results from this ongoing, non-interventional, rollover study were presented at the 23rd Annual Society of Urologic Oncology (SUO) Meeting in San Diego UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company

URGN

2 minute read

Elon Musk Says Tesla Semi ‘As Easy To Drive As Model 3’ At Launch Event

By Shivdeep Dhaliwal

December 1, 9:50 PM

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk launched the company’s Semi commercial truck on Thursday evening.

PEP

1 minute read

Tesla Semi Delivery Event Live on Twitter

By Charles Gross

December 1, 9:12 PM

https://twitter.com/Tesla/status/1598478682527436800?s=20&t=zeIrbvnxXEcrApHdy8SovA

TSLA

3 minute read

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker And Preclinical Data Supporting A Phase 2 Clinical Trial With CT1812 In Geographic Atrophy Secondary To Dry AMD

By Benzinga Newsdesk

December 1, 8:32 AM

Cognition Therapeutics, Inc., (NASDAQ:CGTX), (the "Company" or "Cognition") today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of

CGTX

1 minute read

Events
News

Meta CEO Mark Zuckerberg Speaking At DealBook Conference, Says The “Vast Majority” Of His Time And The Company’s Time Is Still Going To Social Media, Not The Metaverse

By Benzinga Newsdesk

November 30, 3:50 PM

Alex Sherman on Twitter: "Mark Zuckerberg speaking at @dealbook conf — he says the “vast majority” of his time and the company’s time is still going to social media, not the metaverse."

NFTs At Art Basel 2022: 8 Projects To Follow In Miami, From Doodles, Ape Water, A CryptoPunk Donation And More

By Chris Katje

November 30, 1:37 PM

Miami Art Week and Art Basel kick off this week, and the enormous gathering is expected to show the growth of digital art and Web3 evolution inside the art sector.

$DOGE

11 minute read

Reported Late Tuesday, Eisai And Biogen Present Full Results Of Lecanemab Phase 3 Confirmatory Clarity AD Study For Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease Conference: Primary And Key Secondary Endpoints Were Changed From Ba…

By Benzinga Newsdesk

November 30, 2:20 AM

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: , Cambridge, Massachusetts, CEO: , Christopher A.

BIIB

2 minute read

Cathie Wood’s ARK Invest Sells Shares In 2 Manufacturers With Increasing Dividends

By Robert Kuczmarski

November 29, 12:08 PM

For those invested in ARK Invest exchange-traded funds (ETFs) or growth stocks, it may be wise to venture out into value investments or reliable dividend-paying stocks.

ARKK

2 minute read

It’s Cyber Monday: These 2 Mall REITs Are Offering Investors Better Than Average Yields

By Robert Kuczmarski

November 28, 6:21 PM

Using data gathered from Sept. 30, 2019, SP Global reported that over a 10-year period, real estate investment trusts (REITs) dealing with the retail industry had an average annual return of 10.1%.

BRX